Precision BioSciences, Inc.
DTIL
$5.07
$0.112.22%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -99.96% | -99.84% | -90.93% | -95.61% | 152.15% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -99.96% | -99.84% | -90.93% | -95.61% | 152.15% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -99.96% | -99.84% | -90.93% | -95.61% | 152.15% |
| SG&A Expenses | 6.30% | 2.73% | 16.21% | -8.49% | -10.61% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -14.98% | 1.70% | 16.22% | -14.25% | 12.37% |
| Operating Income | -190.60% | -428.11% | -66.86% | -72.09% | 871.68% |
| Income Before Tax | -171.82% | -339.46% | -32.09% | -35.63% | 1,179.76% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -171.82% | -339.46% | -32.09% | -35.63% | 1,179.76% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -171.82% | -339.46% | -8.94% | -103.30% | 375.41% |
| EBIT | -190.60% | -428.11% | -66.86% | -72.09% | 871.68% |
| EBITDA | -185.19% | -613.44% | -79.21% | -91.38% | 2,268.21% |
| EPS Basic | -145.29% | -230.43% | 45.41% | -7.10% | 250.34% |
| Normalized Basic EPS | -144.98% | -224.68% | 42.35% | 27.90% | 679.07% |
| EPS Diluted | -145.61% | -230.43% | 45.35% | -7.10% | 249.24% |
| Normalized Diluted EPS | -145.28% | -224.74% | 42.35% | 27.90% | 675.35% |
| Average Basic Shares Outstanding | 58.56% | 83.60% | 108.24% | 89.83% | 83.18% |
| Average Diluted Shares Outstanding | 57.54% | 83.52% | 108.24% | 89.83% | 84.37% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |